A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Palomino Morales, Rogelio ^a   Gonzalez Juanatey, Carlos ^b   Vazquez Rodriguez, Tomas R ^b   Rodriguez, Luis ^c   Miranda Filloy, Jose A ^b   Fernandez Gutierrez, Benjamin ^c   Llorca, Javier ^d   Martin, Javier ^a   Gonzalez Gay, Miguel A ^b,e  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; COMORBIDITY; DISEASE PREDISPOSITION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; SPAIN;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; COMORBIDITY; DISEASE SUSCEPTIBILITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN;

EID: 77951238604     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2989     Document Type: Article

References (28)

1. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005, 35:8-17. 10.1016/j.semarthrit.2005.03.004, 16084219.
2. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, Stanwix AE. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005, 32:435-442.
3. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloy JA, Ollier WE, Martin J, Llorca J. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132. 10.1002/art.22482, 17266100.
4. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-1155. 10.1056/NEJM199104253241701, 2011158.
5. Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, Putte LB. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999, 58:79-84. 10.1136/ard.58.2.79, 1752831, 10343521.
6. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001, 73:613-621.
7. Hernanz A, Plaza A, Martin-Mola E, De Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999, 32:65-70. 10.1016/S0009-9120(98)00093-9, 10074894.
8. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177. 10.1016/S0140-6736(02)08213-2, 11955534.
9. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998, 25:441-446.
10. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113. 10.1038/ng0595-111, 7647779.
11. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172. 10.1006/mgme.1998.2714, 9719624.
12. Put NM, Gabreëls F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 1998, 62:1044-1051. 10.1086/301825, 1377082, 9545395.
13. Rubini M, Padovan M, Baricordi O, Fotinidi M, Govoni M, Trotta F. The c.1298A>C polymorphism in the methylenetetrahydrofolate reductase gene is associated with rheumatoid arthritis susceptibility in Italian patients. Clin Exp Rheumatol 2008, 26:163. Letter.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
15. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Torres O, Miranda-Filloy JA, Llorca J, Martin J, Gonzalez-Gay MA. Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from Northwestern Spain. Clin Exp Rheumatol 2010, 28:68-72.
16. Pego-Reigosa R, Garcia-Porrua C, Pineiro A, Dierssen T, Llorca J, Gonzalez-Gay MA. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol 2004, 22(Suppl 36):S13-S17.
17. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, Hajeer AH, Ollier WE, Mattey DL, Gonzalez-Gay MA. HLA-DRB1 status influences endothelial dysfunction in long-term treated patients with rheumatoid arthritis. Am J Med 2003, 114:647-652. 10.1016/S0002-9343(03)00133-5, 12798452.
18. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 51:447-450. 10.1002/art.20407, 15188332.
19. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293. 10.1002/art.22530, 17330278.
20. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008, 38:67-70. 10.1016/j.semarthrit.2008.02.001, 18395772.
21. International HapMap Project. , http://hapmap.ncbi.nlm.nih.gov
22. Szczeklik A, Sanak M, Jankowski M, Dropiñski J, Czachór R, Musiał J, Axenti I, Twardowska M, Brzostek T, Tendera M. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 2001, 101:36-39. 10.1002/ajmg.1315, 11343335.
23. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001, 156:409-415. 10.1016/S0021-9150(00)00671-7, 11395038.
24. Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, Pillai R, Ratnatunga C, Tousoulis D, Stefanadis C, Refsum H, Channon KM. MTHFR 677 C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 2009, 119:2507-2515. 10.1161/CIRCULATIONAHA.108.808675, 19398669.
25. Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, Shohat M. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999, 100:2406-2410.
26. Hermans MP, Gala JL, Buysschaert M. The MTHFR CT polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with type 2 diabetes. Diabet Med 2006, 23:529-536. 10.1111/j.1464-5491.2006.01841.x, 16681562.
27. Xin XY, Song YY, Ma JF, Fan CN, Ding JQ, Yang GY, Chen SD. Gene polymorphisms and risk of adult early-onset ischemic stroke: a meta-analysis. Thromb Res 2009, 124:619-24. 10.1016/j.thromres.2009.07.007, 19660787.
28. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR studies collaboration group. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002, 288:2023-2031. 10.1001/jama.288.16.2023, 12387655.